Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil  by Nucci, M. et al.
Invasive fungal diseases in haematopoietic cell transplant recipients and
in patients with acute myeloid leukaemia or myelodysplasia in Brazil
M. Nucci1, M. Garnica1, A. B. Gloria2, D. S. Lehugeur3, V. C. H. Dias4, L. C. Palma5, P. Cappellano6, K. Y. Fertrin7,
F. Carlesse8, B. Simo˜es5, M. D. Bergamasco6, C. A. Cunha4, A. Seber8, M. P. D. Ribeiro1, F. Queiroz-Telles4, M. L. M. Lee8,
M. L. Chauffaille6, L. Silla3, C. A. de Souza7 and A. L. Colombo6
1) University Hospital, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, 2) University Hospital, Federal University of Minas Gerais (UFMG), Belo
Horizonte, 3) University Hospital, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, 4) University Hospital, Federal University of Parana´ (UFPR),
Curitiba, 5) University Hospital, University of Sa˜o Paulo (USP), Ribeira˜o Preto, 6) University Hospital, Federal University of Sa˜o Paulo (UNIFESP), Sa˜o Paulo,
7) Haematology and Haemotherapy Centre, University of Campinas (UNICAMP), Campinas and 8) Institute of Paediatric Oncology, Federal University of
Sa˜o Paulo (UNIFESP), Sa˜o Paulo, Brazil
Abstract
Invasive fungal disease (IFD) shows distinct regional incidence patterns and epidemiological features depending on the geographic region.
We conducted a prospective survey in eight centres in Brazil from May 2007 to July 2009. All haematopoietic cell transplant (HCT)
recipients and patients with acute myeloid leukaemia (AML) or myelodysplasia (MDS) were followed from admission until 1 year (HCT)
or end of consolidation therapy (AML/MDS). The 12-month cumulative incidence (CI) of proven or probable IFD was calculated, and
curves were compared using the Grey test. Among 237 AML/MDS patients and 700 HCT recipients (378 allogeneic, 322 autologous),
the 1-year CI of IFD in AML/MDS, allogeneic HCT and autologous HCT was 18.7%, 11.3% and 1.9% (p <0.001), respectively. Fusariosis
(23 episodes), aspergillosis (20 episodes) and candidiasis (11 episodes) were the most frequent IFD. The 1-year CI of aspergillosis and
fusariosis in AML/MDS, allogeneic HCT and autologous HCT were 13.4%, 2.3% and 0% (p <0.001), and 5.2%, 3.8% and 0.6% (p 0.01),
respectively. The 6-week probability of survival was 53%, and was lower in cases of fusariosis (41%). We observed a high burden of IFD
and a high incidence and mortality for fusariosis in this first multicentre epidemiological study of IFD in haematological patients in Brazil.
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Introduction
Invasive fungal disease (IFD) represents a major complication
in patients with haematological malignancies and in haemato-
poietic cell transplant (HCT) recipients [1,2]. The incidence
and epidemiology of such infections have been characterized
in various retrospective studies [3–17] and a few prospective
studies [18–22] conducted in Europe, the USA and Japan.
However, the incidence and epidemiology of IFD may differ
significantly depending on the geographic region. The knowl-
edge of these epidemiological differences is important to
implement appropriate strategies of prevention, diagnosis
and therapy, and also because of the globalization of the
world, with frequent travelling and migration.
In this paper we report the results of a study that
involved patients with acute myeloid leukaemia (AML) or
myelodysplasia (MDS) receiving intensive chemotherapy and
HCT recipients from eight major referring centres.
Patients and Methods
This is a prospective multicentre cohort study in eight cen-
tres located in seven cities in the south and south-east of
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Brazil. These centres are representative of a substantial pro-
portion of public hospitals performing HCT in Brazil.
Between May 2007 and July 2009, all HCT recipients and all
patients with AML or MDS undergoing induction chemother-
apy for newly diagnosed or relapsed disease were followed
prospectively. Patients receiving palliative care or non-myelo-
toxic induction remission regimens were excluded. The
study was approved by the Institutional Review Board of
each participating centre.
At each centre, one investigator prospectively registered
all new patients with a diagnosis of AML/MDS and all HCT
recipients, followed them throughout the entire period of
observation, and electronically sent data for each phase of
the treatment, until the end of observation. We recorded
demographic data, underlying disease, chemotherapeutic regi-
mens, and for the HCT cohort, details of the transplant
were also recorded, including type of transplant (autologous
or allogeneic), donor (family-related or unrelated), human
leucocyte antigen (HLA) matching (matched, mismatched, i.e.
with some HLA disparity), stem cell source (peripheral
blood, bone marrow or cord blood), and conditioning regi-
men (myeloablative or non-myeloablative).
All centres had high-resolution computed tomography and
automated blood culture systems. Routine serum galacto-
mannan testing was available only during the last 13 months
of the study. The application of the test (as screening or
diagnostic tool) was at the discretion of each centre. If
patients from any of the two cohorts developed an IFD, they
was followed for 3 months, and details of the IFD were
recorded, including clinical manifestations, diagnostic criteria,
aetiology, treatment and the outcome. If a patient developed
more than one episode of IFD, only the first episode was
considered in the analysis. The cases of IFD were classified
by the local investigators, and blindly reviewed and classified
by a data review committee, as proven or probable IFD,
according to the modified European Organization for
Research and Treatment of Cancer/Mycosis Study Group
(EORTC/MSG) criteria [23]. Briefly, proven cases required
either a positive culture from a normally sterile fluid or tis-
sue (urine excluded) or visualization of fungi in tissue,
whereas probable cases were defined on the basis of host
factors, clinical features and mycological criteria. Cases of
possible IFD were excluded.
Patients in the AML/MDS cohort were followed from the
start of the induction remission chemotherapy until the end
of consolidation therapy. Typical duration of neutropenia in
the induction and consolidation phases is 3–4 weeks and 1–
2 weeks, respectively. If the patient was to receive HCT as
consolidation therapy then the patient was censored at that
time, and entered as a new disease episode in the HCT
cohort. In case of relapse or death for a cause not related
to IFD before the end of consolidation therapy, observation
was interrupted and the patient’s status was recorded as
having had a competing event.
Patients in the HCT cohort were followed from condi-
tioning until 1 year post-transplant. If a patient needed to
receive a second HCT, then the patient was censored at that
point, and re-entered in the study as a new disease episode
in the HCT cohort. Except for age and gender, all data are
expressed per disease episode. Relapse of the underlying dis-
ease or death from causes not related to IFD were recorded
as competing events.
Patients were managed according to the routine of each
centre. Neutropenia was defined as an absolute neutrophil
count <0.5 · 103/lL and neutrophil recovery as an abso-
lute neutrophil count ‡0.5 · 103/lL on three consecutive
days.
We calculated the cumulative incidence (CI) of IFD, using
time to first IFD, defined as the date of diagnosis of IFD
minus the first date in the cohort. The date of the diagnosis
of IFD was defined as the date of the first clinical documen-
tation of infection; if the diagnosis was obtained post mor-
tem, the date of death was recorded as the date of diagnosis
of IFD. For the calculation of the CI, we considered relapse
of the underlying disease and death from causes not related
to IFD as competing events. The Grey test was used for
comparison between curves. One-year survival was calcu-
lated using the Kaplan–Meier method and the curves were
compared with the log rank test. We used the CMPRISK pack-
age (R, version 2.14.1) to calculate CI, and the SPSS package
(SPSS, Inc., Chicago, IL version 15.0) for the other analyses.
Results
Characteristics of the patients
During the study period a total of 954 disease episodes were
registered in the database. Eleven disease episodes in the
AML/MDS cohort and six in the HCT cohort were excluded
because of incomplete data. We therefore analysed 937 dis-
ease episodes: 237 induction remission courses of AML/MDS
(in 202 patients) and 700 HCTs (in 673 patients). The med-
ian age of the 875 patients was 37 years (0–82 years), and
56% were male. As shown in Table 1, the most frequent
underlying disease among allogeneic HCT recipients was
AML, followed by acute lymphoid leukaemia, whereas multi-
ple myeloma accounted for 47.5% of autologous HCT. Most
allogeneic HCTs were myeloablative (80.4%), from a
matched related donor (71.7%), with the bone marrow as
the stem cell source (56.1%).
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Invasive fungal diseases
During the study period a total of 108 episodes of IFD were
diagnosed, 66 of which (61%) were proven or probable.
Table 2 shows the classification and aetiology of the 66 proven
or probable IFD. Invasive fusariosis was the leading IFD (23
episodes, including three mixed infections), followed by asper-
gillosis (20 episodes, including one mixed infection), invasive
candidiasis (11 episodes, including one mixed infection) and hy-
alohyphomycosis (eight episodes). Only three cases of muco-
rmycosis were diagnosed, all in allogeneic HCT recipients.
Incidence and outcome of invasive fungal disease
The 1-year CI of all IFD in the entire cohort was 8.7%, and var-
ied from 4.7% to 24.2% in the eight centres. The CI of the dif-
ferent aetiologies of IFD varied among the eight centres. Two
centres did not report any case of invasive aspergillosis (IA),
whereas in two the CI was >7%. Fusariosis was reported in all
but two centres, with five centres reporting CI >3%. Candidia-
sis was reported in four centres and mucormycosis in three.
The 1-year CI of all IFD differed according to patient’s age:
6.5% in patients <18 years, 8.4% in patients aged 19–60 years,
and 14.4% in patients >60 years old (p 0.03). As shown in
Fig. 1, the 1-year CI of all IFD was 18.7% in AML/MDS and
7.2% in HCT (11.3% in allogeneic HCT and 1.9% in autologous
HCT, p <0.001). The 1-year CI of IA in AML/MDS, allogeneic
HCT and autologous HCT was 13.4%, 2.3% and 0%, respec-
tively (p <0.001) (Table 3). No significant differences were
observed in the incidence of IA in the periods before and after
the availability of serum galactomannan in the centres.
The 6-week probability of survival from diagnosis of IFD
was 53% overall. The 6-week probability of survival in
patients with candidiasis, IA and fusariosis was 70%, 63% and
41%, respectively.
Table 4 shows the timing of the occurrence of IFD in the
three cohorts. In the AML/MDS cohort, the median time
from chemotherapy to onset of IFD was 15 days (32–
192 days). The 1-year CI of IFD was not different between
patients receiving chemotherapy as first induction or for the
treatment of relapse (20.1% vs 16.6%, respectively, p 0.76).
The median time from HCT to IFD was 14 days (11–233) in
the autologous cohort, and 53 days (19–232) in the alloge-
neic cohort (p 0.03). The 1-year CI of IFD in matched
TABLE 1. Characteristics of 937 disease episodes in the cohort
Variable
HCT n = 700
AML/MDS n = 237 Total n = 937Allogeneic n = 378 Autologous n = 322
Underlying disease, n (%)
AML 86 (22.8) 10 (3.1) 230 (97.0) 326 (34.8)
MDS 25 (6.6) – 7 (3.0) 32 (3.4)
Multiple myeloma 7 (1.9) 153 (47.5) – 160 (17.1)
Hodgkin’s lymphoma 11 (2.9) 63 (19.6) – 74 (7.9)
Acute lymphocytic leukaemia 70 (18.5) 1 (0.3) – 71 (7.6)
Non-Hodgkin lymphoma 18 (4.8) 50 (15.5) – 68 (7.3)
Aplastic anaemia 56 (14.8) – – 56 (6.0)
Othera 105 (27.7) 45 (14.0) – 150 (15.9)
Type of allogeneic HCT, n (%)
Matched, related 271 (71.7) – – –
Matched, unrelated 14 (3.7) – – –
Mismatched, related 55 (14.6) – – –
Mismatched, unrelated 30 (10.1) – – –
Stem cell source, n (%)
Peripheral blood 128 (33.8) 312 (96.9) – 440/700 (62.9)
Bone marrow 212 (56.1) 10 (3.1) – 222/700 (31.7)
Cord blood 38 (10.1) – – 38/700 (5.4)
Conditioning regimen, n (%)b
Myeloablative 304 (80.4) 302 (93.8) – 606/700 (86.6)
Non-myeloablative 74 (19.6) 20 (6.2) – 94/700 (13.4)
Induction regimen for AML/MDS, n (%)
First induction – – 188 (79.3) –
Relapse – – 49 (20.7) –
Hospitalized in a room with HEPA filter, n (%) 263 (69.6) 249 (77.3) 86 (36.3) 598 (63.8)
Antifungal prophylaxis, n (%) 338 (89.4) 235 (73.0) 133 (56.1) 706 (75.3)
Fluconazole 308 (81.5) 235 (73.0) 125 (52.7)
Itraconazole 2 (0.5) – 5 (2.1) 7 (0.7)
Voriconazole 14 (3.7) – 3 (1.3) 17 (1.8)
d-AMB 14 (3.7) – – 14 (1.5)
Duration (days) of neutropenia, median (range) 15 (2–57) 9 (6–39) 19 (6–86) 12 (2–86)
Duration (days) of follow-up, median (range) 103 (2–365) 103 (11–365) 97 (1–365) 102 (1–365)
HCT, haematopoietic cell transplantation; AML, acute myeloid leukaemia; MDS, myelodysplasia; HEPA, high-efficiency particulate air; d-AMB, deoxycholate amphotericin B.
aOther underlying diseases—Allogeneic HCT: Fanconi anaemia (27), other bone marrow failure syndromes (11), chronic myeloid leukaemia (27), other myeloproliferative dis-
ease (11), congenital immunodeficiency (14), congenital metabolic disease (6), chronic lymphocytic leukaemia (6), and solid tumour, sickle cell anaemia and Langerhans cell his-
tiocytosis (1 each); Autologous HCT: autoimmune disease (27), solid tumour (17), Langerhans cell histiocytosis (1).
bConditioning regimen: allogeneic HCT—most patients with AML received busulfan + cyclophosphamide (48%) or busulfan + fludarabine (24%) and most patients with acute
lymphocytic leukaemia received cyclophosphamide + total body irradiation (49%) or + busulfan (30%); autologous HCT—most patients with lymphoma received carmus-
tine + melphalan + etoposide + cytarabine (61%) or cyclophosphamide + etoposide + carmustine (18%) and most patients with myeloma received melphalan (96%).
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related, matched unrelated, mismatched related and mis-
matched unrelated allogeneic HCT was 11.3%, 9.1%, 7.1%
and 16.4%, respectively (p 0.74).
Discussion
In this first prospective multicentre epidemiological study of
IFD in haematological patients in Latin America, we found a
high burden of IFD in both the AML/MDS and the HCT
cohorts; invasive fusariosis was the leading IFD, followed by
IA.
The incidence of IFD in the present study was expressed
as CI with competing events because this is an appropriate
measure of incidence in a cohort with different durations of
observation and various competing risks [24]. Two studies
reported the incidence of IFD in a similar fashion. In a retro-
spective single-centre study in Japan [9], the 3-year CI of IA
among allogeneic HCT recipients was 5.6%. In the other
study (TRANSNET), prospective data on all HCT performed
in 21 centres in the USA were collected for a period of
approximately 3 years. The 1-year CI of proven + probable
disease was 3.4%, contrasting with the 7.2% CI in the pres-
ent study [19]. This difference is mostly a result of the
higher incidence of fusariosis in our allogeneic HCT cohort
(5.2%), because the CI of IA (2.3% in our cohort and 1.6% in
the other study) was similar.
We did not observe differences in the CI of IFD between
children and younger adults, but a higher incidence was
observed in patients older than 60 years. The higher CI of
IFD in this age group may be related to poor response to
induction chemotherapy in the AML/MDS cohort, and high
transplant-related toxicity, both of which occur in a much
higher proportion of this age group [25,26].
We observed a high CI of IFD in the AML/MDS cohort,
mainly IA and fusariosis. In a prospective study in 17 centres
in Italy, 93 IFD (12.4%) were diagnosed in 747 adults with
AML, 86% of which were caused by moulds [20]. A retro-
spective study from the same group reported a prevalence
of 12% of IFD in patients with AML (2.7% prevalence of IA)
FIG. 1. Cumulative incidence of invasive fungal disease in 237
patients with acute myeloid leukaemia/myelodysplasia, and 378 allo-
geneic and 322 autologous haematopoietic cell transplant recipients.
AML/MDS, acute myeloid leukaemia/myelodysplasia; Allo-HCT, allo-
geneic haematopoietic cell transplantation; Auto-HCT, autologous
haematopoietic cell transplantation.
TABLE 2. Classification and aetiology of 66 proven and probable invasive fungal diseases by underlying condition
Invasive fungal disease
HCT n = 700
AML/MDS n = 237 (%) Total n = 937 (%)Allogeneic n = 378 (%) Autologous n = 322 (%)
Proven 28 (7.4) 5 (1.5) 20 (8.4) 53 (5.6)
Fusariosis 11 (2.9) 2 (0.6) 6 (2.5) 19 (2.0)
Candidiasis 6 (1.6) 2 (0.6) 2 (0.8) 10 (1.1)
Hyalohyphomycosis 4 (1.0) – 4 (1.7) 8 (0.1)
Aspergillosis 1 (0.3) – 8 (3.4) 9 (1.0)
Mucormycosis 3 (0.8) – – 3 (0.3)
Othera 3 1 – 4
Probable 7 (1.8) – 6 (2.5) 13 (1.4)
Aspergillosis 6 (1.6) – 4 (1.7) 10 (1.1)
Fusariosisb 1 (0.3) – – 1 (0.1)
Otherc – – 2 2
Total 35 (9.2) 5 (1.5) 26 (11.0) 66 (7.0)
HCT, haematopoietic cell transplantation; AML, acute myeloid leukaemia; MDS, myelodysplasia.
aOther invasive fungal diseases: cryptococcosis (1, autologous HCT), candidaemia + fusariosis (1, allogeneic HCT), fusariosis + infection due to Colletotrichum sp. (1, allogeneic
HCT), infection due to Rhinocladiella acquaspersa (1, allogeneic HCT).
bProbable fusariosis diagnosed in a patient with typical skin lesions and hyaline hyphae on direct examination and histopathology of skin biopsy but negative culture.
cOther invasive fungal diseases: aspergillosis + fusariosis (1, AML/MDS), infection due to Geotrichum sp. (1, AML/MDS) Total episodes: fusariosis 23, aspergillosis 20, candidiasis
11, mucormycosis 3. Species distribution: Fusariosis—Fusarium solani complex (16), Fusarium oxysporum complex and Fusarium incarnatum (1 each), Fusarium species 5; Candida-
emia—Candida albicans and Candida parapsilosis (3 each), Candida guilliermondii (2), and Candida tropicalis, Candida krusei and Candida famata (1 each); Aspergillosis—Aspergillus
flavus (4), Aspergillus fumigatus (1); 15 cases were diagnosed by positive serum (6) or serum + bronchoalveolar lavage (1) galactomannan antigen, direct exam (1) or biopsy
(7).
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[16]. In another retrospective study, the prevalence of IFD
was 6.7% [11]. Contrary to what we would expect, there
were no differences in the CI between AML patients in first
induction and in relapse, but this may be because of the
small number of relapsed patients in the present study.
We observed a large difference in the CI of IFD between
patient with AML/MDS and those with allogeneic HCT,
mostly because of a higher incidence of IA in the AML/MDS
cohort. The Brazilian public health system reimburses much
less money for AML compared with HCT, which has a sepa-
rate programme and funding. As a consequence, for example,
AML patients are typically cared for in double-bed rooms
without HEPA (high-efficiency particulate air) filters whereas
allogeneic HCT recipients are cared for in single-bed rooms
with HEPA filters and positive pressure. Another possible
reason for these differences is the fact that HCT is usually
an elective procedure in which patients are carefully
selected, whereas patients with AML/MDS represent an
unselected population. Finally, the lower incidence in HCT
could be a result of an increase in non-myeloablative trans-
plants and the use of peripheral blood stem cells, typically
associated with shorter duration of neutropenia, as opposed
to the typical more than 3-week duration of neutropenia
that follows induction remission for AML/MDS.
The time of occurrence of IFD in the present study
showed a typical pattern in which most cases were diag-
nosed during the period of neutropenia of induction chemo-
therapy in the AML/MDS cohort and in autologous HCT
recipients, and was distributed throughout the post-trans-
plant period in allogeneic HCT, as previously reported
[12,13,27].
A remarkable finding of our study was the high 1-year CI
of invasive fusariosis. The TRANSNET study reported 1-year
CI <0.3% for all mould infections [19], and an Italian retro-
spective study reported only three cases of fusariosis among
1249 allogeneic HCT recipients (0.2% prevalence) [16], com-
pared with 3.7% in the present study. In a previous study we
reported a prevalence of 0.6% among HCT recipients
between 1985 and 2001 [28]. The data presented here sug-
gest, therefore, that the incidence of fusariosis in HCT recip-
ients has increased in Brazil. The same was observed in the
AML population, with 3.4% of fusariosis compared with 0.2%
in Italy [15]. A centre effect for the high incidence of invasive
fusariosis is unlikely because only two centres did not report
any case of fusariosis, and the 1-year CI was >3% in five cen-
tres. An investigation in one of the centres showed that in
addition to invasive fusariosis in immunocompromised
patients, there had been an increase in the incidence of
superficial infections in outpatient immunocompetent individ-
uals, suggesting that an increase in environmental reservoirs
of Fusarium have occurred in the region (Nucci et al., submit-
ted).
We found only three cases of mucormycosis, all occurring
in the allogeneic HCT cohort (1-year CI of 0.4%). This is in
contrast with the results of the TRANSNET study that
reported a prevalence of 8% among HCT recipients [19], but
is in accordance with the results of an Italian study, reporting
only one case among 1249 allogeneic HCT recipients [16].
These data illustrate that differences in the incidence of IFD
in different regions of the globe are expected, and may be
caused by multiple factors including patients at risk, degrees
of immunosuppression and local environmental factors.
A limitation of the present study is the fact that galacto-
mannan testing, an important diagnostic tool for IA [29], was
not routinely performed for most of the period of data col-
lection. This may have underestimated the incidence of IA.
Indeed, most of the 42 possible IFD diagnosed in the study
period, and not reported in the present paper, were ‘possi-
ble IA’, i.e. patients with well-circumscribed lung infiltrates
but without microbiological confirmation of IA. In addition,
TABLE 3. Cumulative incidence (1-year) of invasive fungal
diseases by underlying condition
Allogeneic HCT Autologous HCT AML/MDS Total (%)
Fusariosis* 5.2 (%) 0.6 (%) 3.8 (%)
Aspergillosis** 2.3 – 13.4
Candidiasis 2.4 0.6 1.7
Mucormycosis – –
All IFD 11.3 1.9 18.7 8.7
HCT, haematopoietic cell transplantation; AML, acute myeloid leukaemia; MDS,
myelodysplasia; IFD, invasive fungal disease.
*p 0.01; **p <0.001.
TABLE 4. Timing of occurrence of invasive fungal diseases
by underlying condition
Cohort No. of cases
AML/MDS Induction Consolidation –
Aspergillosis 11 1 –
Candidiasis 1 1 –
Fusariosis 6 – –
Other 6 – –






Aspergillosis 2 1 4
Candidiasis 1 4 2
Fusariosis 5 6 3
Mucormycosis 1 2 –
Other 3 3 1






Aspergillosis – 1 –
Candidiasis 2 – –
Fusariosis 2 1 –
Other – – 1a
AML, acute myeloid leukaemia; MDS, myelodysplasia; HCT, haematopoietic cell
transplantation.
aCryptococcosis diagnosed on day 233 in a patient with multiple myeloma.
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the way each centre used the test (as screening or to con-
firm the diagnosis) may have influenced the CI of IA.
Our results have important clinical and research implica-
tions. Given the high incidence of IFD in AML/MDS patients,
antifungal prophylaxis with a mould-active azole such as posa-
conazole seems justifiable [30]. Alternatively, active monitor-
ing with serial (>2·/week) serum galactomannan and images
may help to diagnose these infections early, with a potential
for improving the outcome [31]. In addition, studies (ongoing)
are needed to better characterize the epidemiology of invasive
fusariosis, considering its high incidence in the region.
We conclude that IFD has a high incidence and mortality
in patients with AML/MDS and in HCT recipients in Brazil.
Fusariosis and IA are the leading mycoses, and the incidence
of mucormycosis is low.
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